The Emerging Evidence Supporting Integration of Deep Regional Hyperthermia With Chemoradiation in Bladder Cancer

IF 2.6 3区 医学 Q3 ONCOLOGY Seminars in Radiation Oncology Pub Date : 2023-01-01 DOI:10.1016/j.semradonc.2022.10.011
Oliver J. Ott , Udo S. Gaipl , Allison Lamrani , Rainer Fietkau
{"title":"The Emerging Evidence Supporting Integration of Deep Regional Hyperthermia With Chemoradiation in Bladder Cancer","authors":"Oliver J. Ott ,&nbsp;Udo S. Gaipl ,&nbsp;Allison Lamrani ,&nbsp;Rainer Fietkau","doi":"10.1016/j.semradonc.2022.10.011","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>For decades, the antineoplastic potential of hyperthermia alone or in combination with </span>radiotherapy and/or chemotherapy has been subject of intensive preclinical and </span>clinical research<span><span><span> in various tumor entities. The clinical evidence on the beneficial effects of additional hyperthermia in combination with intravesical Mitomycin C for superficial non-muscle-invasive </span>bladder<span> cancer as well as for deep regional microwave hyperthermia techniques applied during an external beam radiotherapy or </span></span>chemoradiation<span><span> treatment for more advanced tumors are summarized. In some series, deep regional hyperthermia in combination with an initial </span>transurethral resection and Cisplatin-based chemoradiation increased the 5-year overall survival rates up to 20%. The presented data justifies a fresh irrespective chance for mild regional hyperthermia in the context of new progressive prospective trials on multimodality treatment for bladder preservation.</span></span></p></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"33 1","pages":"Pages 82-90"},"PeriodicalIF":2.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053429622000650","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

For decades, the antineoplastic potential of hyperthermia alone or in combination with radiotherapy and/or chemotherapy has been subject of intensive preclinical and clinical research in various tumor entities. The clinical evidence on the beneficial effects of additional hyperthermia in combination with intravesical Mitomycin C for superficial non-muscle-invasive bladder cancer as well as for deep regional microwave hyperthermia techniques applied during an external beam radiotherapy or chemoradiation treatment for more advanced tumors are summarized. In some series, deep regional hyperthermia in combination with an initial transurethral resection and Cisplatin-based chemoradiation increased the 5-year overall survival rates up to 20%. The presented data justifies a fresh irrespective chance for mild regional hyperthermia in the context of new progressive prospective trials on multimodality treatment for bladder preservation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
支持深度局部热疗与放化疗联合治疗膀胱癌的新证据
几十年来,热疗单独或与放疗和/或化疗联合使用的抗肿瘤潜力一直是各种肿瘤实体临床前和临床研究的主题。总结了附加热疗联合膀胱内注射Mitomycin C治疗浅表非肌肉浸润性膀胱癌症的有益效果以及在外束放疗或放化疗治疗更晚期肿瘤时应用的深层区域微波热疗技术的临床证据。在一些系列中,深部区域热疗结合最初的经尿道电切术和基于顺铂的化疗放疗,可将5年总生存率提高20%。所提供的数据证明,在膀胱保存的多模式治疗的新的渐进前瞻性试验中,轻度局部热疗的新机会是合理的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.80
自引率
0.00%
发文量
48
审稿时长
>12 weeks
期刊介绍: Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.
期刊最新文献
Radiation as an Immune Modulator: Where We Are With Modern Total Body Irradiation. Radiation for Multiple Myeloma in the Era of Novel Agents: Indications, Safety, and Dose Selection. Rising to the Top: How Immune-Checkpoint Inhibitors are Changing the Landscape of Treatment for Classic Hodgkin Lymphoma. Translating Between Radiation Dose and Late Toxicity for Lymphoma Survivors: Implications on Toxicity Counseling and Survivorship. Advanced Stage Hodgkin and Diffuse Large B-Cell Lymphomas: Is There Still a Role for Consolidation Radiotherapy in the PET Era?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1